





PATENT ATTORNEY DOCKET NO.: 053665-5010-01

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Louis S. KUCERA et al.

Confirmation No.: 2151

Application No.: 09/844,201

Group Art Unit: 1623

Filed: April 27, 2001

Examiner: Howard Owens, Jr.

For: COMPOSITIONS AND METHODS OF

DOUBLE-TARGETING VIRUS

INFECTIONS AND CANCER CELLS

Attorney Docket No.: 053665-5010-01

### LETTER REGARDING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT SUBMITTED ON OCTOBER 12, 2004

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window Crystal Plaza Two, Lobby, Room 1B03 Arlington, VA 22202

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.97 and 1.98, Applicants submitted a Supplemental Information Disclosure Statement and Form PTO-1449 for the above-identified matter on October 12, 2004 (copy and copy of stamped postcard attached hereto). It is Applicants understanding that somehow the references submitted with the Supplemental Information Disclosure Statement were separated from the Supplemental Information Disclosure Statement. It is also Applicants understanding that the references are currently in the possession of Ms. Linda Poingue of the United States Patent and Trademark Office. Applicants respectfully request that the Supplemental Information Disclosure Statement and Form PTO-1449 for the above-identified matter submitted on October 12, 2004 be connected with the box of references currently in Ms. Poingue's possession.

In addition, Applicants inadvertently did not submit copies of the U.S. patents cited on the PTO-1449 submitted with the October 12, 2004 Supplemental Information Disclosure Statement. Accordingly, Applicants attach hereto copies of each of the U.S. patents cited on the

PTO-1449 submitted with the October 12, 2004 Supplemental Information Disclosure Statement.

No fee is believed to be due for this submission. If any fees are due, please charge the required fees to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: October 13 Z004

By:

Paul E. Dietze

Reg. No. 45,627

**CUSTOMER NO. 09629** 

MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Telephone: (202) 739-3000 Facsimile: (202) 739-3001





### PLEASE STAMP AND RETURN TO SHOW RECEIPT OF:

In re APPLICATION of:

\*\*INVENTOR: Louis S. KUCERA et al.

Appln. No.: 09/844,201

Filed: April 27, 2001

FOR: COMPOSITI

**COMPOSITIONS AND METHODS OF DOUBLE** 

TARGETING VIRUS INFECTIONS AND

**CANCER CELLS** 

**Group No.:** 1623

Examiner: Howard V. Owens, Jr.

 Information Disclosure Statement with PTO-1449 with one box of references and with authorization to charge to Deposit Account No. 50-0310 in the event the PTO deems a fee is necessary

Attorney Docket No.: 053665-5010-01

Dated: October 12, 2004

PED/ats













**PATENT** 

ATTORNEY DOCKET NO.: 053665-5010-01

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Louis S. KUCERA et al.

Confirmation No.: 2151

Application No.: 09/844,201

Group Art Unit: 1623

Filed: April 27, 2001

Examiner: Howard Owens, Jr.

For: COMPOSITIONS AND METHODS OF

DOUBLE-TARGETING VIRUS

INFECTIONS AND CANCER CELLS

Attorney Docket No.: 053665-5010-01

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window Crystal Plaza Two, Lobby, Room 1B03 Arlington, VA 22202

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.97 and 1.98, enclosed is a supplemental Form PTO-1449 which lists 217 references. Copies of the foreign patent documents and other references are enclosed for the Examiner's convenience. Pursuant to the rules pertaining to applications filed after June 30, 2003, copies of the U.S. references are not enclosed.

It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the Form PTO-1449.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c), *i.e.*, before the mailing of a final action under 37 C.F.R. § 1.113. Under 37 C.F.R. §1.97(c)(2) and 37 C.F.R. § 1.17 (p), a fee of \$ 180.00 is due for this submission. Please charge this and any other fee the U.S. Patent and Trademark Office deems is required to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: October 12,2004

By:

zul E. Dietze

Reg. No. 45.627

**CUSTOMER NO. 09629** 

MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004

Telephone: (202) 739-3000 Facsimile: (202) 739-3001

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary) Mail Date

ATTY DOCKET NO.

APPLICATION NO

053665-5010-01

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE

GROUP

April 27, 2001 1623

### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATI
	A01	2,086,585	07/13/1937	Taub et al.	260	127	
<u>.</u>	A02	2,087,132	07/13/1937	Taub et al.	260	127	
	A03	2,108,765	02/15/1938	Domagk	167	30	
	A04	2,209,383	07/30/1940	Bock	8	116	
	A05	2,439,969	04/20/1948	Fourneau	260	338	
	A06	2,445,393	07/20/1948	Fourneau	260	338	
	A07	2,513,747	07/04/1950	Sallman et al.	260	338	
	A08	2,606,909	08/12/1952	Blicke	260	338	
	A09	2,689,790	09/21/1954	Mowry et al.	71	2.7	
· · · · · · · · · · · · · · · · · · ·	A10	2,950,253	08/23/1960	Kling et al.	252	152	
,	A11	3,054,678	09/18/1962	Michener et al.	99	150	
<u></u>	A12	3,694,473	09/26/1972	Eibl et al.	260	403	
,	A13	4,093,714	06/06/1978	Tolman et al.	424	180	
	A14	4,096,278	06/20/1978	Queuille	424	329	
	A15	4,119,714	10/10/1978	Kny et al.	424	199	
	A16	4,159,988	07/03/1979	Eibl et al.	260	340.9R	
	A17	4,221,732	09/09/1980	Oette et al.	260	403	
	A18	4,235,877	11/25/1980	Fullerton	424	89	
	A19	4,291,024	09/22/1981	Turcotte	424	180	
	A20	4,329,302	05/11/1982	Hanahan et al.	260	925	
	A21	4,426,525	01/17/1984	Hozumi et al.	546	22	
	A22	4,444,766	04/24/1984	Bosies et al.	424	211	
	A23	4,471,113	09/11/1984	MacCoss	536	29	
	A24	4,540,521	09/10/1985	Garst et al.	260	459	
	A25	4,619,917	10/28/1986	Lee et al.	514	77	
	A26	4,622,392	11/11/1986	Hong et al.	536	28.5	

### **EXAMINER**

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ATTY DOCKET NO. 053665-5010-01	APPLICATION NO 09/844,201	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Louis S. KUCERA et al.		
	FILING DATE April 27, 2001	GROUP 1623	

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A27	4,661,509	04/28/1987	Gordon et al.	514	397	
	A28	4,724,232	02/09/1988	Rideout et al.	514	50	
	A29	4,797,479	01/10/1989	Shuto et al.	536	28.5	
	A30	4,816,450	03/28/1989	Bell et al.	514	25	
	A31	4,826,823	05/02/1989	Cook et al.	514	46	
	A32	4,835,263	05/30/1989	Nguyen et al.	536	27	
<del></del>	A33	4,837,023	06/06/1989	Eibl	424	439	
	A34	4,841,039	06/20/1989	Chu et al.	536	29	
	A35	4,880,782	11/14/1989	Eckstein et al.	514	45	
	A36	4,921,951	05/01/1990	Shuto et al.	536	28.5	
	A37	4,997,761	03/05/1991	Jett-Tilton	435	375	
	A38	5,026,687	6/25/1991	Yarchoan et al.	514	45	
	A39	5,034,394	07/23/1991	Daluge	514	261	
	A40	5,138,045	08/11/1992	Cook et al.	536	27	
	A41	5,221,696	06/22/1993	Ke et al.	514	786	
	A42	5,496,546	03/05/1996	Wang et al.	424	78.36	
	A43	5,614,548	03/25/1997	Piantadosi et al.	514	440	
	A44	5,633,388	05/27/1997	Diana et al.	548	305.7	
	A45	5,770,584	06/23/1998	Kucera et al.	514	77	
	A46	5,830,905	11/03/1998	Diana et al.	514	322	
	A47	5,846,964	12/08/1998	Ozeki	514	182	
	A48	5,891,874	04/06/1999	Colacino et al.	514	234.5	<u>.                                      </u>
	A49	5,922,757	07/13/1999	Chojkier	514	458	
	A50	5,962,437	4/30/1999	Kucera et al.	514	77	
	A51	6,030,960	02/29/2000	Morris-Natschke et al.	514	77	

EXAMINER	DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# ATTY DOCKET NO. APPLICATION NO 053665-5010-01 09/844,201 APPLICANT (Use several sheets if necessary) Louis S. KUCERA et al. FILING DATE April 27, 2001 1623

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
							YES	NO
	B01	0 094 586	11/23/1983	EPO (English)				
-	B02	0 109 255	05/23/1984	EPO (English)				
	B03	0 142 333	05/22/1985	EPO (English)		-		
	B04	0 145 303	06/19/1985	EPO (English)				
<u> </u>	B05	0 146 258	06/26/1985	EPO (English)				•
	B06	0 252 310	01/13/1988	EPO				
	B07	0 310 109	04/05/1989	EPO (English)				
	B08	0 335 396	04/10/1989	EPO (English)				
	B09	0 350 287	01/10/1990	EPO				
	B10	0 348 859	01/03/1990	EPO (English)				! !
	B11	0 416 401	03/13/1991	EPO				
	B12	0 434 450	06/26/1991	EPO (English)		,		
	B13	0 506 704	07/11/1991	EPO				
	B14	0 632 048	01/04/1995	EPO (English)				
	B15	1,561,630	03/28/1969	France				••••
	B16	199 14 474	10/07/1999	Germany				
	B17	37 26 945 A1	02/23/1989	Germany				
	B18	39 34 820 A1	04/25/1991	Germany				
	B19	40 10 228 A1	10/02/1991	Germany				
	B20	2 239 243 A	06/26/1991	Great Britain			-	

|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# ATTY DOCKET NO. APPLICATION NO 053665-5010-01 09/844,201 APPLICANT (Use several sheets if necessary) Louis S. KUCERA et al. FILING DATE April 27, 2001 1623

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
		1	1 20/0 2/1 2 2	1 -	1		YES	NO
	B21	42-13841	08/05/1967	Japan		7		
	B22	61-238793	10/24/1986	Japan				
	B23	1029312	01/31/1989	Japan				
	B24	49-100224	09/21/1974	Japan				
	B25	08-268890	10/15/1996	Japan				
	B26	10-101591	04/21/1998	Japan				
	B27	90/00555	01/25/1990	WIPO				
	B28	90/05736	05/31/1990	WIPO (English)				
· · · · · · · · ·	B29	90/15601	12/20/1990	WIPO (English)				
	B30	91/05558	05/02/1991	WIPO				
	B31	91/09602	07/11/1991	WIPO				
	B32	91/19726	12/26/1991	WIPO				
	B33	91/18914	12/12/1991	WIPO (English)				
	B34	92/03462	03/05/1992	WIPO				
	B35	92/06192	04/16/1992	WIPO (English)				
	B36	93/08807	05/13/1993	WIPO (English)				-
	B37	93/00910	01/21/1993	WIPO				
	B38	93/16091	08/19/1993	WIPO				
	B39	93/16092	08/19/1993	WIPO			·	<u> </u>
	B40	93/17020	09/02/1993	WIPO (English)				
	B41	93/21191	10/28/1993	WIPO (English)				
	B42	WO 94/28908	12/22/1994	WIPO				
	B43	WO 98/22496	5/28/1998	WIPO (English)				
	B44	WO 98/17679	4/30/1998	WIPO (English)				
	B45	WO 99/07734	2/18/1999	WIPO (English)				
	1 ~							

EXAMINER	DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		T	T		
		ATTY DOCKET NO.	APPLICATION NO		
		053665-5010-01	09/844,201		
LIST OF REFE	RENCES CITED BY APPLICANT	APPLICANT			
	(Use several sheets if necessary)	Louis S. KUCERA et al			
		Doub S. RO CERC I Ci di	•		
		FILING DATE	GROUP		
		April 27, 2001	1623		
	OTHER REFERENCES (Including Author, Tit	tle, Date, Pertinent Pages,	Etc.)		
, C01	Aggarwal, S. K. et al., "Synthesis and Biological Evaluation 10, 1990				
C02	Alt M. et al., "Core Specific Antisense Phosphorothioate Olig Hepatitis C Viral Translation," <u>Archives of Virology</u> 142:589-	-599, 1997			
C03	Alt M. et al., "Specific Inhibition of Hepatitis C Viral GeneEx Oligodeoxynucleotides," <u>Hepatology</u> 22:707-717, September		rothioate		
C04	Amari et al., "Isolation of Experimental Anti-AIDS Glycer High-Performance Liquid Chromatography," Journal of Chromatography,"				
C05					
· C06	Att 1 M D . I would be 1 O . I . CD . (I 1 1 1 ) CIV . (I CIV . NO. A D				
C07					
C08	D 1 (77 ): 077 : 1 7 D 1 (07) 1 1 D 1 (07)				
C09	Boldanova, N. B. et al., "Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis," Vopr. Med. Khim, 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986)				
C10					
C11					
C12	CI N. I WILL CONTROLLED AND AND AND AND AND AND AND AND AND AN				
C13	C1 M + 1 (C) + CC 1 (CC) 1 AND THE C2 CM2 D + 1 T 1 12 C C C C C C C C C C C C C C C C C				
C14					
C15	Crumpton, S. et al., "Novel Lipid Analogs with Cytostatic and Cytocidal Activity," Anticancer Research, Vol. 8, No. 6, pp. 1361-1366, NovDec. 1988				
C16	Daniel, L. W. et al., "Alkyl-Linked Diglygerides Inhibit Pr Biochemical & Biophysical Research Communications, 15	-	Diacylglycerols,"		
C17	Dietzfelbinger, "Cytotoxic and Purging Effects of ET-18-O	OCH3 in Human Malignant Ly	•		
C18	Abstract 2472, Proceedings of the American Assoc. for Car Domawchowske J. B. et al., "Respiratory Syncytial Virus I Treatement." Clinical Microbiology Reviews, 12:208, 200	nfection: Immune Response, l			
	Treatement," Clinical Microbiology Reviews, 12:298-309,	White Taga			

EXAMINER	DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		ATTY DOCKET NO.	APPLICATION NO		
		053665-5010-01	09/844,201		
LIST OF REFE	RENCES CITED BY APPLICANT	APPLICANT			
	(Use several sheets if necessary)	Louis S. KUCERA et al.			
		FILING DATE	GROUP		
		April 27, 2001	1623		
	OTHER REFERENCES (Including Author, Ti	tle, Date, Pertinent Pages,	Etc.)		
· C19	Englund, J. A., "Prevention Strategies for Respiratory Syn 135:38-44, August 1999	cytial Virus: Passive and Activ	ve Immunization," J. Pediatr.,		
C20	Falsey A. R. et al., "Acute Respiratory Tract Infection in Day 1995				
C21	Falsey A. R. et al., "Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings," J Am Geriatric Soc., 40:115-119, 1992				
C22	Fields, A. P. et al., "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor," Nature, 333, 278-80, 19 May 1988				
C23	Galderisi U. et al., "Antisense Oligonucleotides as Therapeutic Agents," <u>Journal of Cellular Physiology</u> , 181:251-257, 1999				
. C24	Glezen W. P. et al., "Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus," Am J Dis Child, 140:543-546, 1986				
C25	Graham, F. L. et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5-DNA," Virology, Vol. 52, pp. 456-467, 1973				
C26	Guerguerian, A. et al., "Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis: a Randomized, Placebo-Controlled Trial," Am J Resp Crit Care Med., 160:829-834, 1999				
C27	Hall C. B. et al., "Infectivity of Respiratory Syncytial Virus by Various Routes of Inoculation," <u>Infect Immun.</u> , 33:779-783, 1981				
C28	T 11 0 D 1 10 T 1 1 1 D 1 1 D 1 T 1 T 1 T 1 T 1 T 1 T				
C29	Hall C. B. et al., "Respiratory Syncytial Virus Infections Within Families," N Engl J Med, 294:414-419, 1976				
C30	Hancock et al., "Analogs of Natural Lipids. VII. Synthesis of Cyclopentanoid Analogs of Phosphatidylcholine," <u>Journal of Lipid Research</u> , Vol. 23, 183-189, 1982				
C31	Harada, S. et al., "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay," Science, 229, 563-566, 9 Aug. 1985				
C32	Hayashi et al., "Antitumor Activity of a Novel Nucleotide Derivative, 5'-(1,2 Dipalmitoyl-sn-glycero-3-phospho)-5-fluorouridine (TJ14026) on Murine Tumors," Biol. Pharm. Bull., 16(8), 778-81, 1993				
C33	Henderson, F.W. et al., "Respiratory-Syncytial-Virus Infections, Reinfections, and Immunity: a Prospective, Longitudinal Study in Young Children," N Engl J Med., 300:530-534, 1979				
C34	Himmelmann, "Studies on the Cross Resistance Pattern of Proceedings of the American Assoc. for Cancer Res., 31, 4	Membrane-Toxic Lipids in Vit	ro," Abstract 2448,		

### \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ATTY DOCKET NO. 053665-5010-01	APPLICATION NO 09/844,201	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Louis S. KUCERA et al.		
	FILING DATE April 27, 2001	GROUP 1623	

•		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
	C35	Hirsch, M. S. et al., "Antiviral Agents," Fields Virology, Third Edition, Lippincott, Raven Publishers, page 431-466, 1996
	C36	Hostetler, et al., "Antiviral Activity of Phosphatidyl-Dideooxycytidine in Hepatitis B-infected Cells and Enhanced Hepatic Uptake in Mice," Antiviral Research,, 59-65, 1994
	C37	Hostetler et al., "Phosphatidylazidothymidine and Phosphatidyl-ddC: Assessment of Uptake in Mouse Lymphoid Tissues and Antiviral Activities in Human Immunodeficiency Virus-Infected Cells and in Rauscher Leukemia Virus-Infected Mice," Antimicrobial Agents and Chemotherapy, Dec. 2792-2797, 1994,
	C38	Hruska, J. F. et al., "In vivo Inhibition of Respiratory Syncytial Virus by Ribavirin," Antimicr Agents Chemother., 21:125-130, 1982
•	C39	Hsu, L. et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides," <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, 1992
	C40	IMPACT RSV Study Group, "Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants," <u>Pediatrics</u> , 102:531-537, 1998
	C41	Jahne et al., "Preparation of Carbocyclic Phosphonate Nucelosides," <u>Tetrahedron Letters</u> , Vol. 33, No. 37, 5335-5338, 1992
	C42	Jayasuriya et al., Design, Synthesis, and Activity of Membrane-Disrupting Bolaphiles," J. Am. Chem. Soc., 112, 5844-5850, 1990
	C43	Jia et al., "Diamide Analogues of Phosphatidylcholine as Potential Anti-AIDS Agents," J. Chem. Soc., 2521-2523, 1993.
	C44	Kakiuchi N. et al., "Non-peptide Inhibitors of HCV Serine Proteinase," J. FEBS Letters, 421:217-220, 1993
	C45	Kasnar, B. et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents," Nucleosides & Nucleotides, 13(1-3), pp. 459-479, 1994
	C46	Kawana, F. et al., "Inhibitory Effects of Antiviral Compounds on Respiratory Syncytial Virus Replication In Vitro," Antimicrob Agents Chemother., August 31, (8):1225-30, 1987
	C47	Korba, B. E. et al., "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication," Antiviral Research, 19, 55-70, 1992
	C48	Krugner-Higby, L., et al., "Membrane-Interactive Phosphilipids Inhibit HIV Type 1-Induced Cell Fusion and Surface gp160/gp120 Binding to Monclonal Antibody," AIDS Research and Human Retroviruses, Vol. 11, 705-712, 1995
	C49	Krugner-Higby, L. A. et al., "Novel Membrane Interactive Ether Lipid Analogs Inhibit HIV-1 Glycoprotein Interaction with CD4 <sup>+</sup> Cells," Abstract 321, 32 <sup>nd</sup> Interscience Conf. on Antimicrobial Agents and Chemotherappy, Anaheim, 164, 11-14 Oct. 1992
	C50	Kucera, L. S., et al., "Activity of Triciribine and Triciribine-5'-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2k" Aids Research and Human Retroviruses, Vol. 9, No. 4, pp. 307-314, 1993

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

		ATTY DOCKET NO.	APPLICATION NO
		053665-5010-01	09/844,201
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	
		Louis S. KUCERA et al.	
		FILING DATE	GROUP
		April 27, 2001	1623
C51	Kucera, "Effect of Membrane-Active Ether Lipid (EL) As	nalogues on Human Immunode	ficiency Virus Production
	Measured by Plaque Assay," Annuals of the New York A		
. C52	Kucera, "Inhibition of HIV-1 Plaque Formation by a Nov International Conference on AIDS, Abstract No. W.C.O.		ther Lipid Analogs,"
C53	Kucera, "Inhibition of Human Immunodeficiency Virus-1		Interactive Ether Lipids,"
	Abstract No. 2470, Proceedings of the American Assoc. f	or Cancer Res., 31, 416, March	1990
C54	Kucera, L., et al., "Inhibition of Human Immunodeficience		-Mediated Cell Fusion by
C55	Synthetic Phospholipid Analogs," Antiviral Research, p. A. Kucera, "Investigations on Membrane Active Ether Lipid		Expression of HIV-1 Induces
CSS	Glycoproteins and Inhibit Pathogenesis," Abstract, Innov		
	Research Triangle Park, 16, 6-9 Dec. 1992		
C56	Kucera, L.S. et al., "In Vitro Evaluation and Characterization of Newly Designed Alkylamidophospholipid Analogue as Anti-Human Immunodeficiency Virus Type 1 Agents," Antiviral Chemistry and Chemotherapy, 9:157-165, 1998		
C57 Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Vir Abstract, ICAAC Orlando, 1994			
C58	Kucera, L. et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Prod Induce Defective Virus Formation," <u>AIDS Research And Human Retroviruses</u> , 6, 491-501, 1990		
C59	Kumar, R., et al., "Equal Inhibition of HIV Replication by		·
Stereospecificity of Lysosomal Phospholipase A <sub>1</sub> ." The Journal of Biological Chemistry, 2			
C60	Lister et al., "Cyclopentanoid Analogs of Phosphatidylcholine: Susceptibility to Phospholipase A <sub>2</sub> ," <u>Journal of Lipid Research</u> , Vol. 29, 1297-1308, 1988.		
C61			
C62	TANK CO. 1. 1. W.C. A. C. A. D. A. C. A. C		
	Round Table Nucleosides, Nucleotides and their Biologic	al Applications, Antwerp, Febru	ary 4-6, p. 255-263,
C62	February 4-6, 1981  C63 Marasco, Jr., C. J., "The Synthesis and Biological Activity of Novel Alkylglycerol Derivatives as Inhibitors		atives as Inhibitors of Protein
C63	Kinase C Activity, Neoplastic Cell Growth, and HIV-1 Infectivity," <u>Dissertation for Ph.D., Univ. of No. Carolina, Chapel Hill</u> , 1990		
C64	Marasco, C. J. et al., "Synthesis and Biological Activity o		
	Alkylglycerols as Potent Inhibitors of Protein Kincase C," March 1990	Journal of Medicinal Chemistr	y, No. 33, pp. 985-992,
C65	Marasco et al., "The Synthesis and Biological Testing of Alkyl Glycerols as Potential Inhibitors of Protein Kinase C," American Assoc. of Pharmaceutical Scientists Abstract, Vol. 9, No. 10, 1992		ibitors of Protein Kinase C,"

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

		ATTY DOCKET NO.	APPLICATION NO	
		053665-5010-01	09/844,201	
LIST OF REFI	ERENCES CITED BY APPLICANT	APPLICANT		
	(Use several sheets if necessary)	Louis S. KUCERA et al.		
		FILING DATE	GROUP	
		April 27, 2001	1623	
	OTHER REFERENCES (Including Author, Ti		Etc.)	
. C66	Marx, M. H. et al., "Synthesis and Evaluation of Neoplast Glycero-3-Phosphocholine," Journal of Medicinal Chemis			
C67				
C68	Deoxyuridine 5'-Phosphate," J. Med. Chem., Vol. 12(5), 8	Mertes et al., "Charge-Spatial Models. cis- and trans-3- and -4- Substituted Cyclohexyl Phosphates as Analogs of 2'- Deoxyuridine 5'-Phosphate," J. Med. Chem., Vol. 12(5), 828-832, 1968		
C69	Meyer, K. L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents," J. Med. Chem, 34, 1377-1383, 1991			
C70	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Li 41, 22-25 Oct. 1989	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids," AAPS Meeting, Atlanta Abstract N. MN-510, p. S-		
C71	Miller, R. H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses," Proc. Natl. Acad. Sci. USA, 83, pp. 2531-2535, April 1986			
C72	Mitsuya, H. et al., "Strategies for Antiviral Therapy in AIDS," Nature, 325, 773-78, 26 February 1987			
C73	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs," Abstract 2471, Proceedings of the American Assoc. for Cancer Res., 31, 416 Abstract 2471, March 1990			
C74	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia,"  Proceedings of the American Association for Cancer Research; Preclinical Pharmacology Experimental Therapeutics, Vol. 31, pp. 416, Abstract 2467, March 1990			
C75	7. 1 . 7 . 1 . (7)			
C76	De la companya del companya de la companya del companya de la comp			
C77	Morrey, J. D. et al., "Effects of Zidovudine on Friend Virus Complex Infection in Rfv-3 <sup>r/s</sup> Genotype-Containing Mice Used as a Model for HIV Infection," <u>Journal of Acquired Immune Deficiency Syndromes</u> , 3, 500-10, 1990			
C78	Morris-Natschke, S. L. et al., "Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of in Vitro Antineoplastic Activity," J. Med. Chem., 36:2018-2025, 1993			
C79	Morris-Natschke, S. et al. "Synthesis of Sulfur Analogues of Alkyl Lysophospholipid and Neoplastic Cell Growth Inhibitory Properties," J. of Med. Chem., 29, 2114-17, 1986			
C80	Mutson, M. A. et al., "Two Distinct Subtypes of Human R Virology, 66:2111-2124, October 1985	espiratory Syncytial Virus," Th	e Journal of General	
C81	Nara, P. L. et al., "Simple, Rapid, Quantitative, Syncytium Immunodeficiency Virus Neutralizing Antibody," AIDS R	_		
C82	Noseda, A. et al., "In Vitro Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive Agents Against Human Tumor Cells," Cancer Research, 48, 1788-1791, April 1, 1988			

EXAMINER	DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		ATTY DOCKET NO.	APPLICATION NO	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		053665-5010-01	09/844,201	
		APPLICANT		
		Louis S. KUCERA et al.		
		FILING DATE	GROUP	
		April 27, 2001	1623	
	OTHER REFERENCES (Including Auth	or, Title, Date, Pertinent Pag	ges, Etc.)	
C83	Noseda, A. et al., "Neoplastic Cell Inhibition with N	New Ether Lipids Analogs," Lipid	s, 22, 878-883, Nov. 1987	
C84	Ostertag, W. et al., "Induction of Endogenous Virus	•	modeoxyuridine in Cell Cultu	
	Transformed by Friend Virus," <u>Proc. Nat. Acad. Sci.</u> Pacheco, D. Y. et al., "Mechanisms of Toxicity of H		Lines " Abstract 2446	
C85	Proceedings of the American Association for Cance	-	Lines, Abstract 2440,	
C86	Painuly et al., "Preparative HPLC of an Experiment Diglyceride (AZT-MP-DG)," Journal of Liquid Chr	•		
C87	Pajouhesh et al., "Synthesis of Polar Head Group He			
	Phosphatidyl-N, N-Dimethylethanolamine, and Pho 303, 1984			
C88	Piantadosi, C. et al., "Synthesis and Evaluation of N	lovel Ether Lipid Nucleoside Con	njugates for Anti-HIV-1 Activi	
C89	J. Med. Chem., 34, 1408-14, 1991 Pidgeon, C. et al., "Anti-HIV Drugs Conjugated to t	he Glycerobackbone of Phosphol	ipids," The Journal of Biologi	
	Chemistry, 7773-7778, 1993  Pidgeon C. et al. "Novel Acyleted Phoenholinid Dr.	was for AIDS "Chamical Abatras	+ 120-60501 1004	
C90	Pidgeon C. et al., "Novel Acylated Phospholipid Dr			
C91	The PREVENT Study Group, "Reduction of Respirato Infants with Bronchopulmonary Dysplasia Using Resp 99:93-99, 1997			
C92	Prince, G. A., "The Pathogenesis of Respiratory Syncy 1978			
C93	C93 Qasim M.A. et al. "Interscaffolding Additivity. Association of P <sub>1</sub> Variants of Eglin c and of Turkey Ovomucoid Third Domain with Serine Proteinases,", <u>Biochemistry</u> 36:1598-1607, 1997		of Turkey Ovomucoid Third	
C94 Qiu et al., "Membrane Properties of Antiviral Phospholipids Containing Heteroatoms in the Acyl C <u>Biochemistry</u> , 33(4), 960-72, 1994  C95 C. Raetz et al., "Phospholipid Derivative of Cytosine Arabinoside and its Conversion to Phosphatid Animal Tissue," <u>Science</u> 196, 303-304, 1977		in the Acyl Chains,"		
C96				
C97 Runge et al., "Destruction of Human solid Tumors by Alkyl Lyso Phospho Lipids," <u>Journal of the National Institute</u> , Vol. 64, 1301-1306, 1980  C98 Sable, C. A. et al., "Orthomyxoviral and Paramyxoviral Infections in Transplant Patients," <u>Infect Dis Clin 1</u> Abstract, 9:987-1003, December 1995		ournal of the National Cancer		
		nts," Infect Dis Clin North An		
C99	Sarin, P. S. et al., "Effects of a Novel Compound (A	· · · · · · · · · · · · · · · · · · ·	Vitro," The New England	
Journal of Medicine, Vol. 313, 1289-90, Nov. 14, 1985  C100 Scolaro M. J. et al., "Inhibition of Virus Replication with Oligonucleotides," Chemical Abstracts, 117:13		l Abstracts, 117:124476, 1992		
C101	Sidoti et al., "Cytostatic Activity of New Synthetic A 717, 1992			
C102	Small, "Characterization of Cells Sensitive and Resi American Assoc. for Cancer Res., 31, 416, March 19		447, Proceedings of the	
XAMINER		DATE CONSIDERED		

1

			ATTY DOCKET NO.	APPLICATION NO	
			053665-5010-01	09/844,201	
LIST C	OF REFE	RENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)			Louis S. KUCERA et al.		
			FILING DATE	GROUP	
			April 27, 2001	1623	
•	C103	Smith, D. W. et al., "A Controlled Trial of Aerosolized Riba Respiratory Syncytial Virus Infection," New England Journa	virin in Infants Receiving Mechan	nical Ventilation for Severe	
•	C104			hate-Digylceride: Anti-HIV	
	C105	0.1 77 . 1 (7.1 11)		plication;" Antiviral Chemistry	
	C106	Sudo K. et al., "Establishment of an In Vitro System for Screen Performance Liquid Chromatography," Antiviral Research 3	2:9-18, 1996		
	C107	Sunamoto, J. et al., "Induction of Cytotoxic T Cell," Cher	mical Abstracts, 117:68365, 199	92	
•	C108	Surles, J. R. et al, "Multigram Synthesis of 1-Alkylamido	Phospholipids," Lipids, 28, 55-	57, 1993	
•	C109	Swayze, E. E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the Tibo Derivative R82150, With Activity Against Human Immunodeficiency Virus," <u>Bioorganic &amp; Medical Chemistry Letters</u> , Vol. 3, No. 4, pp 543-546, 1993		ted to the Tibo Derivative	
	C110 Takeshita N. et al., "An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Proteinase," Analytical Biochemistry 247:242-246, May 1, 1997			vity of Hepatitis C Virus	
	C111 Tarnowski et al., "Effect of Lyso Lecithin and Analogs on Mouse Ascites," Cancer Research, Vol. 38, 33		rch, Vol. 38, 339-344, 1978		
	C112	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprot Mediated Cell Fusion," Abstracts of the 2nd National Conference on Human Retroviruses, Session 18, 1995			
	C113	Tiollais, P., et al., "Hepatitis B. Virus," Scientific Americ			
	C114 Van Wijk et al., "Synthesis and Antiviral Activity of 3'-azido-3'deoxythymidine Triphosphate Distearoylglycerol Novel: Phospholipid Conjugate of the Anti-HIV Agent AZT," Chemistry and Physics of Lipids, 70, 213-222, 199				
	Van Wijk, G. M. et al., "Spontaneous and Protein-Mediated Intermembrance Transfer of the Antiretroviral Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceride," Biochemistry, 31, 5912-5917, June 30, 1992			the Antiretroviral	
	C116				
	C117	Wang, E. E. et al., "Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Prospective Study of Risk Factors and Outcomes in Patients Hospitalized with Respiratory Syncytial Viral Lower Respiratory Tract Infection," Abstract, J Pediatr, 126:212-219, February 1995			
	C118	7774 1 1 70 1 1 1/0		Bone Marrow Transplant	
	C119	Yamaue, H. et al., "Chemosensitivity Testing with Highly Colorimetric Assay," Abstract, Eur J Cancer, 27:1258-126	53, 1991		
	C120	Yanagawa, H. et al. "Spontaneous Formation of Superhelic 111, 4567-70, June 21, 1989			
	C121	Yarchoan, R. et al., "Therapeutic Strategies in the Treatment of AIDS," <u>Annual Reports in Medicinal Chemistry</u> , Vo 23, 253-263, 1988		n Medicinal Chemistry, Vol.	

EXAMINER	DATE CONSIDERED
	<del></del>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.